| Clascoterone | Sun Pharma | ||
| 1%; Cream |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
None | ||
| None | None | ||
| WINLEVI® (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. | |||
|
Yes
| |||
| Winlevi | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| ********* | ******* **** *** | **** ** *** **, **** | ******* **** *** | ******* **** *** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** **** **, **** (***** ******) |
| ********* ******* *** ********* ** *****-********** ** *********** ***/** *** *,**-****************** | ********* ******* *** ********* ** α-********** ** *********** ***/** *** *,**-****************** | ********* ******* *** ********* ** *****-********** ** *********** ***/** *** *,**-****************** | ********* ******* *** ********* ** *****-********** ** *********** ***/** *** *,**-****************** | **α, **-***************** ****** ** ************** ****** | ********* ******* *** ********* ** *****-********** ** *********** ***/** *** *,**-****************** | ******, **-***************** ****** ** ************** ****** | ** *****, **-***************** ****** ** ************** ****** | ********* ******* *** ********* **α-********** ** *********** ***/** *** *,**-****************** | ********* ******* *** ********* ** *****-********** ** *********** ***/** *** *,**-****************** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ********* | *** \ ********* | *** **, **** | ******* | **** | ******* *** **** *** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|